2Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis,1998;26:1 ～ 12
3Schentag JJ, Smith IL, Swanson DJ, et al. Role for dual individualization with cefmenoxime. Am J Med, 1984 ;77:43 ～ 50
4Kashuba AD, Nafziger AN, Drusano GL, et al. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gramnegative bacteria. Antimicrob Agents Chemother, 1999; 43:623 ～ 629
5Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother, 1993 ;37: 1073 ～ 1081
6Andes D, Anon J, Jacobs MR, et al. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections. Clin Lab Med, 2004 ;24:477～ 502
7Burgess DS. Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance. Chest, 1999; 115: 19S ～ 23S
二级参考文献3
1[1]Craig W A. Pharmacokinetic/pharmacodynamic parameters:rationale for antibacterial dosing of mice and men[J]. Clin lnfect Dis, 1998, 26: 1-12.
2[2]Nightingale C H, Murakawa T, Ambrose P G, et al. Antimicrobial pharmacodynamics in theory and clinical practice[M]. New York: Marcel Dekker, InC. 2002. 385-408.
3[3]Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: A general strategy derived from fluoroquinolone studies[J]. Clin lnfect Dis, 2001, 33: 147-156.
